TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
10x Genomics Sweden AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
156,109
|
271,033
|
242,422 |
| Financial expenses |
81
|
316
|
8 |
| Earnings before taxes |
66,104
|
155,837
|
128,483 |
| EBITDA |
67,284
|
165,516
|
137,499 |
| Total assets |
109,715
|
375,057
|
246,318 |
| Current assets |
109,715
|
355,768
|
219,627 |
| Current liabilities |
25,964
|
35,706
|
53,166 |
| Equity capital |
83,751
|
339,350
|
193,153 |
| - share capital |
52
|
51
|
47 |
| Employees (average) |
19
|
39
|
45 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
76.3%
|
90.5%
|
78.4% |
| Turnover per employee |
8,216
|
6,950
|
5,387 |
| Profit as a percentage of turnover |
42.3%
|
57.5%
|
53.0% |
| Return on assets (ROA) |
60.3%
|
41.6%
|
52.2% |
| Current ratio |
422.6%
|
996.4%
|
413.1% |
| Return on equity (ROE) |
78.9%
|
45.9%
|
66.5% |
| Change turnover |
-119,811
|
11,409
|
91,854 |
| Change turnover % |
-43%
|
4%
|
61% |
| Chg. No. of employees |
-20
|
-6
|
7 |
| Chg. No. of employees % |
-51%
|
-13%
|
18% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.